Botulinum Toxin Injections for Neurogenic Detrusor Overactivity Medication

Updated: Mar 06, 2019
  • Author: Pamela I Ellsworth, MD; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print
Medication

Neuromuscular Blockers, Botulinum Toxins

Class Summary

Agents in this class cause presynaptic paralysis of the myoneural junction and reduce abnormal contractions.

Onabotulinumtoxin A (BOTOX)

Botulinum toxin may provide relief of spasticity without the systemic adverse effects of other antispasticity agents. Binds to receptor sites on the motor nerve terminals and, after uptake, inhibits the release of acetylcholine, blocking transmission of impulses in neuromuscular tissue.

In treating adult patients for 1 or more indications, the maximum cumulative dose generally should not exceed 360 U in a 3-month period. The recommended treatment dose of onabotulinumtoxin A is 200 U per treatment, divided into 30 injections of 1 mL.